l -天冬酰胺酶药物治疗急性淋巴细胞白血病的毒性研究

Q4 Medicine

Oncogematologiya Pub Date : 2023-09-13 DOI:10.17650/1818-8346-2023-18-3-134-139

T. T. Valiev

{"title":"l -天冬酰胺酶药物治疗急性淋巴细胞白血病的毒性研究","authors":"T. T. Valiev","doi":"10.17650/1818-8346-2023-18-3-134-139","DOIUrl":null,"url":null,"abstract":"Currently no therapy of acute lymphoblastic leukemia is conceivable without L-asparaginase drugs, with its antileukemic effect by extracellular asparagine depletion, thus preventing its admission to leukemic cell. Besides high antitumor effect, L-asparaginase drugs have side and toxic effects, such as hypersensitivity reactions, thrombosis, pancreatitis / pancreatic necrosis, and hepatotoxicity. For L-asparaginase safety profile improvement a technology of pegylation was lay down and PEG-aspargase drug produced. This drug has less toxic effects and recommended as first-line therapy of acute lymphoblastic leukemia. Drug monitoring for assessment the effectiveness and toxicity of L-asparaginase is optimal. Such therapy individualization helps for L-asparaginase dose finding and decrease frequency and severity of side effects.","PeriodicalId":37536,"journal":{"name":"Oncogematologiya","volume":"20 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Toxicity of L-asparaginase drugs in acute lymphoblastic leukemia treatment\",\"authors\":\"T. T. Valiev\",\"doi\":\"10.17650/1818-8346-2023-18-3-134-139\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Currently no therapy of acute lymphoblastic leukemia is conceivable without L-asparaginase drugs, with its antileukemic effect by extracellular asparagine depletion, thus preventing its admission to leukemic cell. Besides high antitumor effect, L-asparaginase drugs have side and toxic effects, such as hypersensitivity reactions, thrombosis, pancreatitis / pancreatic necrosis, and hepatotoxicity. For L-asparaginase safety profile improvement a technology of pegylation was lay down and PEG-aspargase drug produced. This drug has less toxic effects and recommended as first-line therapy of acute lymphoblastic leukemia. Drug monitoring for assessment the effectiveness and toxicity of L-asparaginase is optimal. Such therapy individualization helps for L-asparaginase dose finding and decrease frequency and severity of side effects.\",\"PeriodicalId\":37536,\"journal\":{\"name\":\"Oncogematologiya\",\"volume\":\"20 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncogematologiya\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17650/1818-8346-2023-18-3-134-139\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncogematologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1818-8346-2023-18-3-134-139","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

目前，没有l -天冬酰胺酶药物治疗急性淋巴细胞白血病是不可想象的，其抗白血病作用是通过细胞外天冬酰胺的消耗，从而防止其进入白血病细胞。l -天冬酰胺酶药物除具有较高的抗肿瘤作用外，还存在过敏反应、血栓形成、胰腺炎/胰腺坏死、肝毒性等毒副作用。为了提高l -天冬酰胺酶的安全性，提出了聚乙二醇化技术，并生产了聚乙二醇-天冬酰胺酶药物。该药毒性作用小，推荐作为急性淋巴细胞白血病的一线治疗药物。对l -天冬酰胺酶的有效性和毒性进行药物监测是最理想的。这种个体化治疗有助于发现l -天冬酰胺酶的剂量，减少副作用的发生频率和严重程度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Toxicity of L-asparaginase drugs in acute lymphoblastic leukemia treatment

Currently no therapy of acute lymphoblastic leukemia is conceivable without L-asparaginase drugs, with its antileukemic effect by extracellular asparagine depletion, thus preventing its admission to leukemic cell. Besides high antitumor effect, L-asparaginase drugs have side and toxic effects, such as hypersensitivity reactions, thrombosis, pancreatitis / pancreatic necrosis, and hepatotoxicity. For L-asparaginase safety profile improvement a technology of pegylation was lay down and PEG-aspargase drug produced. This drug has less toxic effects and recommended as first-line therapy of acute lymphoblastic leukemia. Drug monitoring for assessment the effectiveness and toxicity of L-asparaginase is optimal. Such therapy individualization helps for L-asparaginase dose finding and decrease frequency and severity of side effects.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncogematologiya Medicine-Hematology

CiteScore

0.50

自引率

0.00%

发文量

审稿时长

10 weeks

期刊介绍： The main purpose of the Oncohematology journal is to publish up-to-date information on clinical, experimental and fundamental scientific research, diagnostics and treatment options, as well as other materials on all relevant issues in oncohematology. The journal’s objectives are to inform various specialists who provide advisory and therapeutic assistance to patients with oncohematological diseases about current advances, including the latest methods for the diagnosis and treatment of malignant blood diseases. The journal is an interdisciplinary scientific publication uniting doctors of various specialties ‒ hematologists, oncologists, surgeons, radiation therapists, intensive care specialist, pathologists, etc. ‒ to form an interdisciplinary therapy approach in order to improve the treatment efficacy of patients with hematological malignancies.